<p>在谷歌搜索和人工智能答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开谷歌</p>
<p>在谷歌上添加</p>
<p>圣地亚哥，2026 年 7 月 13 日（全球新闻稿）——Erasca, Inc.（纳斯达克：ERAS），一家专注于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症患者的疗法的临床阶段精准肿瘤学公司，今天宣布其增量公开发行 31,428,572 股普通股的定价。这些普通股的公开售价为每股 17.50 美元。所有将在公开发行中出售的普通股均由 Erasca 出售。Erasca 预计此次发行的毛收益在扣除承销折扣和佣金及其他发行费用之前约为 5.5 亿美元。此外，Erasca 已授予承销商一个 30 天的选择权，以发行额外的 4,714,285 股普通股，价格为发行价，扣除承销折扣和佣金。此次发行预计将于 2026 年 7 月 15 日完成，前提是满足惯例的交割条件。</p>
<p>Erasca 打算将此次发行的净收益与其现有现金、现金等价物和可交易证券结合使用，以资助其产品候选者的研究和开发以及其他开发项目，并用于营运资金和其他一般企业用途。</p>
<p>摩根大通、摩根士丹利、杰富瑞和 Evercore ISI 担任此次发行的联合账簿管理人。</p>
<p>上述证券是根据 Erasca 提交的 S-3 表格的货架注册声明进行发行的，包括之前于 2026 年 7 月 13 日向证券交易委员会（SEC）提交并在提交时自动生效的基本招股说明书。</p>
<p>与此次发行相关的初步招股说明书补充已向 SEC 提交，最终招股说明书补充也将向 SEC 提交。此次发行仅可通过招股说明书补充和随附的招股说明书进行。当可用时，最终招股说明书补充及随附的招股说明书的副本可从以下地址获取：摩根大通证券公司，c/o Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；摩根士丹利公司，注意：招股说明书部门，180 Varick Street，2 楼，纽约，纽约 10014，或通过电子邮件发送至 prospectus@morganstanley.com；杰富瑞公司，注意：股权承销招股说明书部门，520 Madison Avenue，纽约，NY 10022，电话（877）821-7388，或通过电子邮件发送至 Prospectus_Department@Jefferies.com；以及 Evercore Group L.L.C.，注意：股权资本市场，55 East 52nd Street，35 楼，纽约，NY 10055，电话（888）474-0200，或通过电子邮件发送至 ecm.prospectus@evercore.com。最终招股说明书补充及随附的招股说明书的电子副本也将在 SEC 网站上提供，网址为 http://www.sec.gov。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，除非在该州或司法管辖区的证券法下进行注册或资格审查。</p>
<p><strong>关于 Erasca</strong></p>
<p>在 Erasca，我们的名字就是我们的使命：消灭癌症。我们是一家专注于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症患者的疗法的临床阶段精准肿瘤学公司。我们的公司由精准肿瘤学和 RAS 靶向领域的领先先驱共同创立，旨在创造新型疗法和组合方案，全面关闭 RAS/MAPK 通路，以治疗癌症患者。我们相信，我们团队的能力和经验，加上我们的科学顾问委员会的指导，其中包括 RAS/MAPK 通路领域的世界顶尖专家，使我们独特地具备实现消灭癌症这一大胆使命的能力。</p>
<p><strong>前瞻性声明</strong></p>
<p>Erasca 提醒您，本新闻稿中关于非历史事实的声明属于前瞻性声明。前瞻性声明基于我们当前的信念和预期，包括但不限于：我们对发行的预期关闭和预计收益使用的预期。由于市场条件和与发行相关的惯例交割条件的满足，以及我们在之前向 SEC 提交的文件中描述的业务固有的风险和不确定性，实际结果可能与本新闻稿中所述的结果有所不同。我们提醒您，不要对这些前瞻性声明过于依赖，这些声明仅在本日期有效，我们没有义务更新这些声明以反映本日期后发生的事件或存在的情况。所有前瞻性声明均完全受到本警示声明的限制，该声明根据 1995 年《私人证券诉讼改革法》的安全港条款作出。</p>
<p><strong>联系方式：</strong></p>
<p>Joyce Allaire</p>
<p>LifeSci Advisors, LLC</p>
<p>jallaire@lifesciadvisors.com</p>
<p>来源：Erasca, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjMk1UWXlOaU0zTnpBME5qZzNJelV3TURBNU9EWXpOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjMk1UWXlOaU0zTnpBME5qZzNJelV3TURBNU9EWXpOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NhMzAxNjctMDU4ZC00ZGU0LTkzOWYtYjkzNDg4Y2YwYTE1LTUwMDA5ODYzNC0yMDI2LTA3LTE0LWVu/tiny/Erasca-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NhMzAxNjctMDU4ZC00ZGU0LTkzOWYtYjkzNDg4Y2YwYTE1LTUwMDA5ODYzNC0yMDI2LTA3LTE0LWVu/tiny/Erasca-Inc-.png"/></p>

ERAS

<p>Erasca, Inc.（纳斯达克代码：ERAS）宣布以每股 17.50 美元的价格增发 31,428,572 股普通股，筹集约 5.5 亿美元的总收入。公司计划将净收入用于研发、营运资金和一般企业用途。此次发行预计将于 2026 年 7 月 15 日完成</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在谷歌搜索和人工智能答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开谷歌</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在谷歌上添加</p>
</div><p>SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock.The shares of common stock are being sold to the public at a price of $17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $550.0 million.In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 4,714,285 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>圣地亚哥，2026 年 7 月 13 日（全球新闻稿）——Erasca, Inc.（纳斯达克：ERAS），一家专注于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症患者的疗法的临床阶段精准肿瘤学公司，今天宣布其增量公开发行 31,428,572 股普通股的定价。这些普通股的公开售价为每股 17.50 美元。所有将在公开发行中出售的普通股均由 Erasca 出售。Erasca 预计此次发行的毛收益在扣除承销折扣和佣金及其他发行费用之前约为 5.5 亿美元。此外，Erasca 已授予承销商一个 30 天的选择权，以发行额外的 4,714,285 股普通股，价格为发行价，扣除承销折扣和佣金。此次发行预计将于 2026 年 7 月 15 日完成，前提是满足惯例的交割条件。</p>
</div><p>Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>Erasca 打算将此次发行的净收益与其现有现金、现金等价物和可交易证券结合使用，以资助其产品候选者的研究和开发以及其他开发项目，并用于营运资金和其他一般企业用途。</p>
</div><p>J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>摩根大通、摩根士丹利、杰富瑞和 Evercore ISI 担任此次发行的联合账簿管理人。</p>
</div><p>The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) on July 13, 2026 and automatically became effective upon filing.</p>
<div class="lb-trans"><p>上述证券是根据 Erasca 提交的 S-3 表格的货架注册声明进行发行的，包括之前于 2026 年 7 月 13 日向证券交易委员会（SEC）提交并在提交时自动生效的基本招股说明书。</p>
</div><p>A preliminary prospectus supplement relating to this offering has been filed with the SEC and a final prospectus supplement relating to this offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.</p>
<div class="lb-trans"><p>与此次发行相关的初步招股说明书补充已向 SEC 提交，最终招股说明书补充也将向 SEC 提交。此次发行仅可通过招股说明书补充和随附的招股说明书进行。当可用时，最终招股说明书补充及随附的招股说明书的副本可从以下地址获取：摩根大通证券公司，c/o Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；摩根士丹利公司，注意：招股说明书部门，180 Varick Street，2 楼，纽约，纽约 10014，或通过电子邮件发送至 prospectus@morganstanley.com；杰富瑞公司，注意：股权承销招股说明书部门，520 Madison Avenue，纽约，NY 10022，电话（877）821-7388，或通过电子邮件发送至 Prospectus_Department@Jefferies.com；以及 Evercore Group L.L.C.，注意：股权资本市场，55 East 52nd Street，35 楼，纽约，NY 10055，电话（888）474-0200，或通过电子邮件发送至 ecm.prospectus@evercore.com。最终招股说明书补充及随附的招股说明书的电子副本也将在 SEC 网站上提供，网址为 http://www.sec.gov。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，除非在该州或司法管辖区的证券法下进行注册或资格审查。</p>
</div><p><strong>About Erasca</strong></p>
<div class="lb-trans"><p><strong>关于 Erasca</strong></p>
</div><p>At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.</p>
<div class="lb-trans"><p>在 Erasca，我们的名字就是我们的使命：消灭癌症。我们是一家专注于发现、开发和商业化针对 RAS/MAPK 通路驱动癌症患者的疗法的临床阶段精准肿瘤学公司。我们的公司由精准肿瘤学和 RAS 靶向领域的领先先驱共同创立，旨在创造新型疗法和组合方案，全面关闭 RAS/MAPK 通路，以治疗癌症患者。我们相信，我们团队的能力和经验，加上我们的科学顾问委员会的指导，其中包括 RAS/MAPK 通路领域的世界顶尖专家，使我们独特地具备实现消灭癌症这一大胆使命的能力。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the expected closing of the offering and the anticipated use of proceeds therefrom. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</p>
<div class="lb-trans"><p>Erasca 提醒您，本新闻稿中关于非历史事实的声明属于前瞻性声明。前瞻性声明基于我们当前的信念和预期，包括但不限于：我们对发行的预期关闭和预计收益使用的预期。由于市场条件和与发行相关的惯例交割条件的满足，以及我们在之前向 SEC 提交的文件中描述的业务固有的风险和不确定性，实际结果可能与本新闻稿中所述的结果有所不同。我们提醒您，不要对这些前瞻性声明过于依赖，这些声明仅在本日期有效，我们没有义务更新这些声明以反映本日期后发生的事件或存在的情况。所有前瞻性声明均完全受到本警示声明的限制，该声明根据 1995 年《私人证券诉讼改革法》的安全港条款作出。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Joyce Allaire</p>
<div class="lb-trans"><p>Joyce Allaire</p>
</div><p>LifeSci Advisors, LLC</p>
<div class="lb-trans"><p>LifeSci Advisors, LLC</p>
</div><p>jallaire@lifesciadvisors.com</p>
<div class="lb-trans"><p>jallaire@lifesciadvisors.com</p>
</div><p>Source: Erasca, Inc.</p>
<div class="lb-trans"><p>来源：Erasca, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjMk1UWXlOaU0zTnpBME5qZzNJelV3TURBNU9EWXpOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTc2MTYyNiM3NzA0Njg3IzUwMDA5ODYzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2NhMzAxNjctMDU4ZC00ZGU0LTkzOWYtYjkzNDg4Y2YwYTE1LTUwMDA5ODYzNC0yMDI2LTA3LTE0LWVu/tiny/Erasca-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/M2NhMzAxNjctMDU4ZC00ZGU0LTkzOWYtYjkzNDg4Y2YwYTE1LTUwMDA5ODYzNC0yMDI2LTA3LTE0LWVu/tiny/Erasca-Inc-.png"/></p>

Erasca Announces Pricing of Upsized Public Offering of Common Stock | ERAS Stock News

StockTitan

Erasca

摩根大通

摩根士丹利

Jefferies Financial

Evercore

布罗德里奇金融解决方案

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Erasca 宣布扩大普通股公开发行的定价 | ERAS 股票新闻